All News
Rheumatoid arthritis and lung disease in the spotlight at #ACR20
Rheumatoid arthritis (RA) has long been established to have pulmonary manifestations such as interstitial lung disease (ILD), and several research groups are pursuing this respiratory burden of RA at #ACR20.
Read Article
FAST, FREED, CARES, & CONFIRMS: A Run-Down on the Black-Box Blues of Febuxostat
Febuxostat, a nonpurine xanthine oxidase inhibitor used in the treatment of chronic gout to lower serum urate levels, received bad press in 2019 after the US Food and Drug Administration (FDA) placed a black-box warning on the medication’s label suggesting that it increases the risk of cardiovasc
Read Article
Lung Cancer Survival With Autoimmune Disease--a recent analysis suggests that patients with autoimmune disease do not have worse survival, even though they may have received less than the standard-of-care treatments.
Learn more below.
https://t.co/ItVhityI1B https://t.co/tyTKAtGY2O
Links:
Dr. John Cush RheumNow ( View Tweet)
Phase III RHAPSODY trial: open label rilonacept in 86 pts with active recurrent pericarditis (& elevated CRP). Rapid resolution was noted and during the drug withdrawal phase there were significantly fewer recurrences on rilonacept compared with placebo. https://t.co/oEGbsdKe8f
Links:
Dr. John Cush RheumNow ( View Tweet)
#UTSW Rheum Grand Rounds on Sarcoidosis w/ Dr. HSIA - Joints are involved in 15% of pts. Lung sking and ocular involvement predominate https://t.co/G4iWm4pLmO
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @drdavidliew :The 'triple M' irAEs (myositis/myocarditis/MG): one of the rheumatic irAEs where autoAb are freq pos
Nice systematic review:
any autoAb+ 61% tested
MG+ 59% tested
MSA+ in 27% tested (18/67, 11 had myositis alone) https://t.co/aQHapPbjw9
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @MeralElRamahiMD : A large observat study showed no difference in risk of major CV events in RA pts that were newly started on either MTX or HCQ. A greater stroke risk but lower risk of MI; hospitalized HF was seen in MTX initiators. #Abst1993 #ACR20
Dr. John Cush RheumNow ( View Tweet)
The Lungs: The Alpha and Omega of RA with Dr. Jonathan Kay #ACR20
https://t.co/zhCRaeKOfu https://t.co/zVwgzu9ULs
Links:
Dr. John Cush RheumNow ( View Tweet)
Citrulline Reactive B Cells Present in Lungs of Risk, Early RA: Richard Conway ( @RichardPAConway) discusses ACR abstract #1445 presented #ACR20
https://t.co/WjcBPay86P https://t.co/JnUVss0FDK
Links:
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets
RT @KDAO2011 : The FAST trial had 33% of pts with CVD and pts w/class III/IV CHF weren't allowed in this study; still cautious prescribing febuxostat to pts who have severe CVD until we have more data. https://t.co/eyl2kOjEEU https://t.co/qoQDgRifFg
Links:
Dr. John Cush RheumNow ( View Tweet)
Check out this quick video on lifestyle, clinical risk factors for RA-ILD with Dr. Sheila Reyes (@RHEUMarampa) #ACR20
https://t.co/7LQ7RCtiuj https://t.co/CjjtUauy2u
Links:
Dr. John Cush RheumNow ( View Tweet)
"Rheumatoid arthritis and lung disease in the spotlight at #ACR20" by Dr. Jeffrey Sparks ( @jeffsparks)
https://t.co/0Dth0ko5TO https://t.co/e6HQOkXuY7
Links:
Dr. John Cush RheumNow ( View Tweet)
View our video on Abatacept in RA and ILD Patients with Dr Richard Conway ( @RichardPAConway)
Dr. Richard Conway discusses abstract #0233 presented Friday at the #ACR20 virtual annual meeting.
https://t.co/5zowsDetU1
Links:
Dr. John Cush RheumNow ( View Tweet)
#ACR20 Abstracts on #ILD
Rituximab in ILD (all observational)
#1053 ➡️ 47 with CTD-ILD: overall improvement or stability at 36m
#1051 ➡️ 50 with IPAF: >70% stable or improved at 12m
#1047 ➡️ 47 patients CTD-ILD or IPAF: good experience with MMF and RTX
#ACRambassador https://t.co/klfVwIH5b6
Sebastian E. Sattui MD, MS SattuiSEMD ( View Tweet)
Latebreaking at #ACR20—Febuxostat was non-inferior to allopurinol with regard to the occurrence of major cardiovascular outcomes in patients with gout: finding from FAST, multicentre, prospective, randomised, open-label, non-inferiority trial https://t.co/cpoNi7zjwi https://t.co/uQyeyepPmj
Links:
The Lancet TheLancet ( View Tweet)
The FAST trial had 33% of pts with CVD and pts w/class III/IV CHF were not allowed in this study (vs. CARES trial where all subjects had baseline CVD); I am still cautious prescribing febuxostat to pts who have severe CVD until we have more data. @RheumNow https://t.co/fJ9bLcXpR2
k dao KDAO2011 ( View Tweet)
IN GOUT: CARES study said febuxostat increases CV risk; Todays FAST study says No incr CV risk w/ FEB. In your Gout pt w/ CV hx, would you use febuxostat? #ACR2020
Dr. John Cush RheumNow ( View Tweet)
FAST trial (Plenary) showed opposite of CAREs study. Febuxostat vs PBO in 6128 Gout pts, showed little dropout (~6%) in a 4 year study. Febuxostat (mean 81mg) had similar, flare rates, MACE/cardiac endpoints and CV death vs allopurinol #ACR20 Abstr#L08 https://t.co/FkdDtPB4Oi https://t.co/J9KonQHpT2
Dr. John Cush RheumNow ( View Tweet)
A large observat study showed no difference in risk of major CV events in RA pts that were newly started on either MTX or HCQ. A greater stroke risk but lower risk of MI & hospitalized HF was seen in MTX initiators. #Abst1993 #ACR20 @RheumNow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Abatacept in RA and ILD Patients: Dr Richard Conway (@RichardPAConway) #ACR20
https://t.co/e31VsnXFq5 https://t.co/sCrqLtXFFc
Links:
Dr. John Cush RheumNow ( View Tweet)
